Siemens Healthineers ( (SEMHF) ) has released its Q4 earnings. Here is a breakdown of the information Siemens Healthineers presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Siemens Healthineers AG is a leading global healthcare company specializing in medical technology and diagnostics, known for its innovative solutions in imaging, diagnostics, and advanced therapies.
In its fiscal year 2025 earnings report, Siemens Healthineers announced a strong financial performance despite challenging market conditions. The company reported a significant increase in revenue and profitability, driven by robust growth in its Imaging and Varian segments.
Key financial metrics for the year included a 5.9% comparable revenue growth and an adjusted EBIT margin of 16.5%, which is an improvement from the previous year. The Imaging segment saw a notable 6.5% revenue growth in the fourth quarter, while the Diagnostics segment improved its EBIT margin significantly due to cost reductions. The Varian segment also demonstrated strong performance with a 1.4% revenue increase in the fourth quarter.
Despite higher tariffs impacting margins, Siemens Healthineers managed to achieve a free cash flow of €2.7 billion, reflecting a substantial increase from the previous year. The company proposed a dividend of €1.00 per share, up from €0.95, signaling confidence in its financial stability and future prospects.
Looking ahead to fiscal year 2026, Siemens Healthineers expects continued revenue growth between 5% to 6% and anticipates adjusted basic earnings per share to range between €2.20 and €2.40, indicating a stable outlook despite potential macroeconomic challenges.